S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV).
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
26
07
2020
accepted:
14
01
2021
entrez:
18
5
2021
pubmed:
19
5
2021
medline:
21
5
2021
Statut:
ppublish
Résumé
Dermatitis herpetiformis (DH) is a chronic, pruritic, gluten-induced skin disorder characterized by subepidermal granular IgA deposition and a variable degree of enteropathy identical to that seen in coeliac disease. So far, there has been no European consensus about the management of DH. The guidelines were created by small subgroups of a guideline committee consisting of 26 specialists from various medical fields and one patients' representative. The members of the committee then discussed the guidelines and voted for the final version at two consensus meetings. The guidelines were developed under the support of the European Academy of Dermatology and Venereology (EADV) and in collaboration with the European Dermatology Forum (EDF). The guidelines summarize evidence-based and expert-based recommendations (S2 level) for the management of DH (see Appendix). These guidelines will improve the quality of management of DH and support dermatologists in their diagnostic and therapeutic decisions.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1251-1277Subventions
Organisme : EADV
Informations de copyright
© 2021 European Academy of Dermatology and Venereology.
Références
Duhring L. Dermatitis herpetiformis. JAMA 1884; III: 225-229.
Marks J, Shuster S, Watson AJ. Small-bowel changes in dermatitis herpetiformis. Lancet 1966; 2: 1280-1282.
Cormane RH. Immunofluorescent studies of the skin in lupus erythematosus and other diseases. Pathol Eur 1967; 2: 170-180.
van der Meer JB. Granular deposits of immunoglobulins in the skin of patients with dermatitis herpetiformis. An immunofluorescent study. Br J Dermatol 1969; 81: 493-503.
Chorzelski TP, Sulej J, Tchorzewska H, Jablonska S, Beutner EH, Kumar V. IgA class endomysium antibodies in dermatitis herpetiformis and coeliac disease. Ann N Y Acad Sci 1983; 420: 325-334.
Karpati S, Meurer M, Stolz W, Schrallhammer K, Krieg T, Braun-Falco O. Dermatitis herpetiformis bodies. Ultrastructural study on the skin of patients using direct preembedding immunogold labeling. Arch Dermatol 1990; 126: 1469-1474.
Dieterich W, Ehnis T, Bauer M et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997; 3: 797-801.
Sardy M, Karpati S, Merkl B, Paulsson M, Smyth N. Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med 2002; 195: 747-757.
Di Sabatino A, Corazza GR. Coeliac disease. Lancet 2009; 373: 1480-1493.
Ohata C, Ishii N, Hamada T et al. Distinct characteristics in Japanese dermatitis herpetiformis: a review of all 91 Japanese patients over the last 35 years. Clin Dev Immunol 2012; 2012: 562168.
Spurkland A, Ingvarsson G, Falk ES, Knutsen I, Sollid LM, Thorsby E. Dermatitis herpetiformis and celiac disease are both primarily associated with the HLA-DQ (alpha 1*0501, beta 1*02) or the HLA-DQ (alpha 1*03, beta 1*0302) heterodimers. Tissue Antigens 1997; 49: 29-34.
Ohata C, Ishii N, Niizeki H et al. Unique characteristics in Japanese dermatitis herpetiformis. Br J Dermatol 2016; 174: 180-183.
Salmi TT, Hervonen K, Kautiainen H, Collin P, Reunala T. Prevalence and incidence of dermatitis herpetiformis: a 40-year prospective study from Finland. Br J Dermatol 2011; 165: 354-359.
Antiga E, Verdelli A, Calabro A, Fabbri P, Caproni M. Clinical and immunopathological features of 159 patients with dermatitis herpetiformis: an Italian experience. G Ital Dermatol Venereol 2013; 148: 163-169.
Bolotin D, Petronic-Rosic V, Dermatitis herpetiformis. J Am Acad Dermatol 2011; 64: 1017-1024.
West J, Fleming KM, Tata LJ, Card TR, Crooks CJ. Incidence and prevalence of celiac disease and dermatitis herpetiformis in the UK over two decades: population-based study. Am J Gastroenterol 2014; 109: 757-768.
Smith JB, Tulloch JE, Meyer LJ, Zone JJ. The incidence and prevalence of dermatitis herpetiformis in Utah. Arch Dermatol 1992; 128: 1608-1610.
Milinkovic MV, Jankovic S, Medenica L et al. Incidence of autoimmune bullous diseases in Serbia: a 20-year retrospective study. J Dtsch Dermatol Ges 2016; 14: 995-1005.
Mansikka E, Salmi T, Kaukinen K et al. Diagnostic delay in dermatitis herpetiformis in a high-prevalence area. Acta Derm Venereol 2018; 98: 195-199.
Husby S, Koletzko S, Korponay-Szabo I et al. European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020. J Pediatr Gastroenterol Nutr 2020; 70: 141-156.
Mansikka E, Hervonen K, Kaukinen K et al. Prognosis of dermatitis herpetiformis patients with and without villous atrophy at diagnosis. Nutrients 2018; 10: 641.
Ferguson A, Blackwell JN, Barnetson RS. Effects of additional dietary gluten on the small-intestinal mucosa of volunteers and of patients with dermatitis herpetiformis. Scand J Gastroenterol 1987; 22: 543-549.
Popp A, Maki M. Gluten-induced extra-intestinal manifestations in potential celiac disease-celiac trait. Nutrients 2019; 11: 320.
Korponay-Szabo IR, Halttunen T, Szalai Z et al. In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies. Gut 2004; 53: 641-648.
Kurppa K, Koskinen O, Collin P, Maki M, Reunala T, Kaukinen K. Changing phenotype of celiac disease after long-term gluten exposure. J Pediatr Gastroenterol Nutr 2008; 47: 500-503.
Karell K, Korponay-Szabo I, Szalai Z et al. Genetic dissection between coeliac disease and dermatitis herpetiformis in sib pairs. Ann Hum Genet 2002; 66: 387-392.
Barbara HJM. Dermatitis herpetiformis. In Jonkman MF, ed. Autoimmune Bullous Diseases: Text and Review, Springer International Publishing, Berlin, 2016: 173-181.
Antiga E, Caproni M. The diagnosis and treatment of dermatitis herpetiformis. Clin Cosmet Investig Dermatol 2015; 8: 257-265.
Fabbri P, Caproni M. Dermatitis herpetiformis. Orphanet Encíclopaedia 2003 (uptadate 2005).
Fry L. Dermatitis herpetiformis: problems, progress and prospects. Eur J Dermatol 2002; 12: 523-531.
Nicolas ME, Krause PK, Gibson LE, Murray JA. Dermatitis herpetiformis. Int J Dermatol 2003; 42: 588-600.
Yeh SW, Ahmed B, Sami N, Ahmed RA. Blistering disorders: diagnosis and treatment. Dermatol Ther 2003; 16: 214-223.
Handa S, Dabas G, De D et al. A retrospective study of dermatitis herpetiformis from an immunobullous disease clinic in north India. Int J Dermatol 2018; 57: 959-964.
Criado PR, Chiacchio NG, Santos LD. Dermoscopy examination of petechial lesions in a patient with Dermatitis Herpetiformis. An Bras Dermatol 2013; 88: 817-819.
Lopez Aventin D, Ilzarbe L, Herrero-Gonzalez JE. Recurrent digital petechiae and weight loss in a young adult. Gastroenterology 2013; 144: e10-11.
Perez-Garcia MP, Mateu-Puchades A, Soriano-Sarrio MP. A 26-year-old woman with palmar petechiae. Int J Dermatol 2013; 52: 1493-1494.
Tu H, Parmentier L, Stieger M et al. Acral purpura as leading clinical manifestation of dermatitis herpetiformis: report of two adult cases with a review of the literature. Dermatology 2013; 227: 1-4.
Zaghi D, Witheiler D, Menter AM. Petechial eruption on fingers. Dermatitis herpetiformis. JAMA Dermatol 2014; 150: 1353-1354.
Hull CMZJ. Dermatitis herpetiformis and linear IgA bullous dermatosis. In Bolognia J, Schaffer J, Cerroni L, eds. Dermatology. Elsevier, Amsterdam, 2018: 527-537.
Lahteenoja H, Irjala K, Viander M, Vainio E, Toivanen A, Syrjanen S. Oral mucosa is frequently affected in patients with dermatitis herpetiformis. Arch Dermatol 1998; 134: 756-758.
Patinen P. Oral findings in dermatitis herpetiformis and coeliac disease. In: Institute of Dentistry and Institute of Clinical Medicine, University of Helsinki and Hospital for Skin and Allergic Diseases. Hospital for Children and Adolescents Huslab / Oral Pathology Unit and Department of Oral and Maxillofacial Surgery, Helsinki University Central Hospital and Departments of Otorhinolaryngology and Maxillofacial Surgery, Internal Medicine and Dermatology, Tampere University Hospital, Tampere, Finland, 2004.
Aine L, Maki M, Reunala T. Coeliac-type dental enamel defects in patients with dermatitis herpetiformis. Acta Derm Venereol 1992; 72: 25-27.
Reunala T, Salmi TT, Hervonen K, Kaukinen K, Collin P. Dermatitis herpetiformis: a common extraintestinal manifestation of coeliac disease. Nutrients 2018; 10: 602.
Caproni M, Antiga E, Melani L, Fabbri P. Guidelines for the diagnosis and treatment of dermatitis herpetiformis. J Eur Acad Dermatol Venereol 2009; 23: 633-638.
Alonso-Llamazares J, Gibson LE, Rogers RS 3rd. Clinical, pathologic, and immunopathologic features of dermatitis herpetiformis: review of the Mayo Clinic experience. Int J Dermatol 2007; 46: 910-919.
Kaplan RP, Callen JP. Dermatitis herpetiformis: autoimmune disease associations. Clin Dermatol 1991; 9: 347-360.
Reunala T. Incidence of familial dermatitis herpetiformis. Br J Dermatol 1996; 134: 394-398.
Reunala T, Collin P. Diseases associated with dermatitis herpetiformis. Br J Dermatol 1997; 136: 315-318.
Warren SJ, Cockerell CJ. Characterization of a subgroup of patients with dermatitis herpetiformis with nonclassical histologic features. Am J Dermatopathol 2002; 24: 305-308.
Zone JJ, Meyer LJ, Petersen MJ. Deposition of granular IgA relative to clinical lesions in dermatitis herpetiformis. Arch Dermatol 1996; 132: 912-918.
Dmochowski M, Gornowicz-Porowska J, Bowszyc-Dmochowska M. An update on direct immunofluorescence for diagnosing dermatitis herpetiformis. Postepy Dermatol Alergol 2019; 36: 655-658.
Dmochowski M, Bowszyc-Dmochowska M, Dańczak-Pazdrowska A. On patterns of IgA deposits in the skin of patients with dermatitis herpetiformis. Postepy Dermatol Alergol 2003; 20: 46-48.
Ko CJ, Colegio OR, Moss JE, McNiff JM. Fibrillar IgA deposition in dermatitis herpetiformis-an underreported pattern with potential clinical significance. J Cutan Pathol 2010; 37: 475-477.
Gornowicz-Porowska J, Bowszyc-Dmochowska M, Seraszek-Jaros A, Kaczmarek E, Dmochowski M. Association between levels of IgA antibodies to tissue transglutaminase and gliadin-related nonapeptides in dermatitis herpetiformis. ScientificWorldJournal 2012; 2012: 363296.
Barnadas MA. Dermatitis Herpetiformis: a review of direct immunofluorescence findings. Am J Dermatopathol 2016; 38: 283-288.
Hashimoto T, Tsuruta D, Yasukochi A et al. Granular C3 dermatosis. Acta Derm Venereol 2016; 96: 748-753.
Mustakallio KK, Blomqvist K, Salo OP. Papillary fibrin in dermatitis herpetiformis. Arch Belg Dermatol Syphiligr 1970; 26: 441-447.
Salo OP, Laiho K, Blomqvist K, Mustakallio KK. Papillary deposition of fibrin in iodide reactions in dermatitis herpetiformis. Ann Clin Res 1970; 2: 19-21.
Jakubowicz K, Dabrowski J, Maciejewski W. Deposition of fibrin-like material in early lesions of dermatitis herpetiformis. Ann Clin Res 1971; 3: 34-38.
Gorog A, Nemeth K, Szabo L et al. Decreased fibrinolytic potential and morphological changes of fibrin structure in dermatitis herpetiformis. J Dermatol Sci 2016; 84: 17-23.
Bonciolini V, Antiga E, Bianchi B et al. Granular IgA deposits in the skin of patients with coeliac disease: is it always dermatitis herpetiformis? Acta Derm Venereol 2019; 99: 78-83.
Cannistraci C, Lesnoni La Parola I, Cardinali G et al. Co-localization of IgA and TG3 on healthy skin of coeliac patients. J Eur Acad Dermatol Venereol 2007; 21: 509-514.
Beutner EH, Baughman RD, Austin BM, Plunkett RW, Binder WL. A case of dermatitis herpetiformis with IgA endomysial antibodies but negative direct immunofluorescent findings. J Am Acad Dermatol 2000; 43: 329-332.
Bresler SC, Granter SR. Utility of direct immunofluorescence testing for IgA in patients with high and low clinical suspicion for dermatitis herpetiformis. Am J Clin Pathol 2015; 144: 880-884.
Huber C, Trueb RM, French LE, Hafner J. Negative direct immunofluorescence and nonspecific histology do not exclude the diagnosis of dermatitis herpetiformis Duhring. Int J Dermatol 2013; 52: 248-249.
Hallstrom O. Comparison of IgA-class reticulin and endomysium antibodies in coeliac disease and dermatitis herpetiformis. Gut 1989; 30: 1225-1232.
Seah PP, Fry L, Holborow EJ et al. Antireticulin antibody: incidence and diagnostic significance. Gut 1973; 14: 311-315.
Dahlbom I, Korponay-Szabo IR, Kovacs JB, Szalai Z, Maki M, Hansson T. Prediction of clinical and mucosal severity of coeliac disease and dermatitis herpetiformis by quantification of IgA/IgG serum antibodies to tissue transglutaminase. J Pediatr Gastroenterol Nutr 2010; 50: 140-146.
Kumar V, Jarzabek-Chorzelska M, Sulej J, Rajadhyaksha M, Jablonska S. Tissue transglutaminase and endomysial antibodies-diagnostic markers of gluten-sensitive enteropathy in dermatitis herpetiformis. Clin Immunol 2001; 98: 378-382.
Volta U, Molinaro N, De Franchis R et al. Correlation between IgA antiendomysial antibodies and subtotal villous atrophy in dermatitis herpetiformis. J Clin Gastroenterol 1992; 14: 298-301.
Leonard MM, Sapone A, Catassi C, Fasano A. Celiac disease and nonceliac gluten sensitivity: a review. JAMA 2017; 318: 647-656.
Sardy M, Karpati S, Peterfy F et al. Comparison of a tissue transglutaminase ELISA with the endomysium antibody test in the diagnosis of gluten-sensitive enteropathy. Z Gastroenterol 2000; 38: 357-364.
Olen O, Gudjonsdottir AH, Browaldh L et al. Antibodies against deamidated gliadin peptides and tissue transglutaminase for diagnosis of pediatric celiac disease. J Pediatr Gastroenterol Nutr 2012; 55: 695-700.
Kasperkiewicz M, Dähnrich C, Probst C et al. Novel assay for detecting celiac disease-associated autoantibodies in dermatitis herpetiformis using deamidated gliadin-analogous fusion peptides. J Am Acad Dermatol 2012; 66: 583-588.
Sugai E, Hwang HJ, Vázquez H et al. New serology assays can detect gluten sensitivity among enteropathy patients seronegative for anti-tissue transglutaminase. Clin Chem 2010; 56: 661-665.
Jaskowski TD, Donaldson MR, Hull CM et al. Novel screening assay performance in pediatric celiac disease and adult dermatitis herpetiformis. J Pediatr Gastroenterol Nutr 2010; 51: 19-23.
Lytton SD, Antiga E, Pfeiffer S et al. Neo-epitope tissue transglutaminase autoantibodies as a biomarker of the gluten sensitive skin disease-dermatitis herpetiformis. Clin Chim Acta 2013; 415: 346-349.
Antiga E, Bonciolini V, Cazzaniga S et al. Female patients with dermatitis herpetiformis show a reduced diagnostic delay and have higher sensitivity rates at autoantibody testing for celiac disease. Biomed Res Int 2019; 2019: 6307035.
Velikova T, Shahid M, Ivanova-Todorova E et al. Celiac-related autoantibodies and IL-17A in Bulgarian patients with dermatitis herpetiformis: a Cross-Sectional Study. Medicina (Kaunas) 2019; 55: 136.
Kim CY, Quarsten H, Bergseng E, Khosla C, Sollid LM. Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci USA 2004; 101: 4175-4179.
Lundin KE, Gjertsen HA, Scott H, Sollid LM, Thorsby E. Function of DQ2 and DQ8 as HLA susceptibility molecules in celiac disease. Hum Immunol 1994; 41: 24-27.
Paulsen G, Lundin KE, Gjertsen HA, Hansen T, Sollid LM, Thorsby E. HLA-DQ2-restricted T-cell recognition of gluten-derived peptides in celiac disease. Influence of amino acid substitutions in the membrane distal domain of DQ beta 1*0201. Hum Immunol 1995; 42: 145-153.
Hadithi M, von Blomberg BM, Crusius JB et al. Accuracy of serologic tests and HLA-DQ typing for diagnosing celiac disease. Ann Intern Med 2007; 147: 294-302.
Hill P, Austin A, Forsyth J, Holmes G. British Society of Gastroenterology guidelines on the diagnosis and management of coeliac disease. Gut 2015; 64: 691-692.
Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol 2013; 108: 656-676; quiz 677.
Schmidt E, Goebeler M, Hertl M et al. S2k guideline for the diagnosis of pemphigus vulgaris/foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges 2015; 13: 713-727.
Bodd M, Tollefsen S, Bergseng E, Lundin KE, Sollid LM. Evidence that HLA-DQ9 confers risk to celiac disease by presence of DQ9-restricted gluten-specific T cells. Hum Immunol 2012; 73: 376-381.
Ch'ng CL, Jones MK, Kingham JG. Celiac disease and autoimmune thyroid disease. Clin Med Res 2007; 5: 184-192.
Kahaly GJ, Frommer L, Schuppan D. Celiac disease and endocrine autoimmunity - the genetic link. Autoimmun Rev 2018; 17: 1169-1175.
Minelli R, Gaiani F, Kayali S et al. Thyroid and celiac disease in pediatric age: a literature review. Acta Biomed 2018; 89: 11-16.
Volta U, Caio G, Stanghellini V, De Giorgio R. The changing clinical profile of celiac disease: a 15-year experience (1998-2012) in an Italian referral center. BMC Gastroenterol 2014; 14: 194.
Valitutti F, Iorfida D, Anania C et al. Cereal consumption among subjects with celiac disease: a snapshot for nutritional considerations. Nutrients 2017; 9: 396.
Anania C, Pacifico L, Olivero F, Perla FM, Chiesa C. Cardiometabolic risk factors in children with celiac disease on a gluten-free diet. World J Clin Pediatr 2017; 6: 143-148.
Brar P, Kwon GY, Holleran S et al. Change in lipid profile in celiac disease: beneficial effect of gluten-free diet. Am J Med 2006; 119: 786-790.
Norsa L, Shamir R, Zevit N et al. Cardiovascular disease risk factor profiles in children with celiac disease on gluten-free diets. World J Gastroenterol 2013; 19: 5658-5664.
Wei L, Spiers E, Reynolds N, Walsh S, Fahey T, MacDonald TM. The association between coeliac disease and cardiovascular disease. Aliment Pharmacol Ther 2008; 27: 514-519.
Zanini B, Mazzoncini E, Lanzarotto F et al. Impact of gluten-free diet on cardiovascular risk factors. A retrospective analysis in a large cohort of coeliac patients. Dig Liver Dis 2013; 45: 810-815.
Deora V, Aylward N, Sokoro A, El-Matary W. Serum vitamins and minerals at diagnosis and follow-up in children with celiac disease. J Pediatr Gastroenterol Nutr 2017; 65: 185-189.
Wierdsma NJ, van Bokhorst-de van der Schueren M, Berkenpas M, Mulder C, van Bodegraven AD. Vitamin and mineral deficiencies are highly prevalent in newly diagnosed celiac disease patients. Nutrients 2013; 5: 3975-3992.
Burger JPW, van der Laan JJH, Jansen TA et al. Low yield for routine laboratory checks in follow-up of coeliac disease. J Gastrointestin Liver Dis 2018; 27: 233-239.
Trovato CM, Albanese CV, Leoni S et al. Lack of clinical predictors for low mineral density in children with celiac disease. J Pediatr Gastroenterol Nutr 2014; 59: 799-802.
Kemppainen T, Kröger H, Janatuinen E et al. Bone recovery after a gluten-free diet: a 5-year follow-up study. Bone 1999; 25: 355-360.
Lucendo AJ, Garcia-Manzanares A. Bone mineral density in adult coeliac disease: an updated review. Rev Esp Enferm Dig 2013; 105: 154-162.
Heikkila K, Pearce J, Maki M, Kaukinen K. Celiac disease and bone fractures: a systematic review and meta-analysis. J Clin Endocrinol Metab 2015; 100: 25-34.
Di Stefano M, Jorizzo RA, Veneto G, Cecchetti L, Gasbarrini G, Corazza GR. Bone mass and metabolism in dermatitis herpetiformis. Dig Dis Sci 1999; 44: 2139-2143.
Valdimarsson T, Lofman O, Toss G, Strom M. Reversal of osteopenia with diet in adult coeliac disease. Gut 1996; 38: 322-327.
Lewis NR, Logan RF, Hubbard RB, West J. No increase in risk of fracture, malignancy or mortality in dermatitis herpetiformis: a cohort study. Aliment Pharmacol Ther 2008; 27: 1140-1147.
Pasternack C, Kaukinen K, Kurppa K et al. Gastrointestinal symptoms increase the Burden of illness in dermatitis herpetiformis: a prospective study. Acta Derm Venereol 2017; 97: 58-62.
Amber KT, Murrell DF, Schmidt E, Joly P, Borradori L. Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management. Clin Rev Allergy Immunol 2018; 54: 26-51.
Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunol Res 2018; 66: 255-270.
Fortuna G, Marinkovich MP. Linear immunoglobulin A bullous dermatosis. Clin Dermatol 2012; 30: 38-50.
Wojnarowska F, Marsden RA, Bhogal B, Black MM. Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults. A comparative study demonstrating clinical and immunopathologic overlap. J Am Acad Dermatol 1988; 19: 792-805.
Sheridan AT, Kirtschig G, Wojnarowska F. Mixed immunobullous disease: is this linear IgA disease? Australas J Dermatol 2000; 41: 219-221.
Witte M, Zillikens D, Schmidt E. Diagnosis of autoimmune blistering diseases. Front Med (Lausanne) 2018; 5: 296.
Sticherling M, Erfurt-Berge C. Autoimmune blistering diseases of the skin. Autoimmun Rev 2012; 11: 226-230.
Mendes FB, Hissa-Elian A, Abreu MA, Goncalves VS. Review: dermatitis herpetiformis. An Bras Dermatol 2013; 88: 594-599.
Barbosa WS, Rodarte CM, Guerra JG, Maciel VG, Fleury Junior LF, Costa MB. Bullous systemic lupus erythematosus: differential diagnosis with dermatitis herpetiformis. An Bras Dermatol 2011; 86(4 Suppl 1): S92-S95.
Kasperkiewicz M, Orosz I, Abeck D, Koletzko S, Ruzicka T, Sardy M. Childhood epidermolysis bullosa acquisita with underlying coeliac disease. Acta Derm Venereol 2015; 95: 1013-1014.
Powell GR, Bruckner AL, Weston WL. Dermatitis herpetiformis presenting as chronic urticaria. Pediatr Dermatol 2004; 21: 564-567.
Saito M, Boer A, Ishiko A, Nishikawa T. Atypical dermatitis herpetiformis: a Japanese case that presented with initial lesions mimicking prurigo pigmentosa. Clin Exp Dermatol 2006; 31: 290-291.
Moderer M, Korting HC, Yazdi A. [Grover's disease following hemodialysis in a patient with renal failure]. J Dtsch Dermatol Ges 2004; 2: 203-205.
Lu CI, Yang CH, Hong HS. A bullous neutrophilic dermatosis in a patient with severe rheumatoid arthritis and monoclonal IgA gammopathy. J Am Acad Dermatol 2004; 51(2 Suppl): S94-96.
Bonciolini V, Bianchi B, Del Bianco E, Verdelli A, Caproni M. Cutaneous manifestations of non-celiac gluten sensitivity: clinical histological and immunopathological features. Nutrients 2015; 7: 7798-7805.
Faina V, Paolino G, Bavastrelli M, Calvieri S, Grieco T. Classification of cutaneous manifestations in patients with non-celiac gluten sensitivity (NCGS) and wheat allergy (WA). J Am Acad Dermatol 2017; S0190-9622: 32811-32816.
Bolotin D, Petronic-Rosic V. Dermatitis herpetiformis. Part II. Diagnosis, management, and prognosis. J Am Acad Dermatol 2011; 64: 1027-1033; quiz 1033-1024.
Collin P, Salmi TT, Hervonen K, Kaukinen K, Reunala T. Dermatitis herpetiformis: a cutaneous manifestation of coeliac disease. Ann Med 2017; 49: 23-31.
Rai S, Kaur A, Chopra CS. Gluten-free products for celiac susceptible people. Front Nutr 2018; 5: 116.
Shewry PRPY, Lafiandra D et al. Wheat glutenin subunits and dough elasticity: findings of the EUROWHEAT project. Trends Food Sci Technol 2001; 11: 433-441.
Mehtab W, Singh N, Malhotra A, Makharia GK. All that a physician should know about gluten-free diet. Indian J Gastroenterol 2018; 37: 392-401.
Gatti S, Caporelli N, Galeazzi T et al. Oats in the diet of children with celiac disease: preliminary results of a double-blind, randomized, placebo-controlled multicenter Italian study. Nutrients 2013; 5: 4653-4664.
(EC). CR. No. 41/2009 concerning the composition and labelling of food stuffs suitable for people intolerant to gluten. In: Off J Eur Union L., 2009; 3-5.
(EC). CR. No. 1169/2011 concerning the provision of food information to consumers. In: Off J Eur Union L 2011; 18-63.
(EC). CR. No. 828/2014 concerning the requirements for the provision of information to consumers on the absence or reduced presence of gluten in food. In: Off J Eur Union L, 2014; 228/5.
Catassi C, Fabiani E, Iacono G et al. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr 2007; 85: 160-166.
Koerner TB, Cleroux C, Poirier C et al. Gluten contamination of naturally gluten-free flours and starches used by Canadians with celiac disease. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2013; 30: 2017-2021.
Hallert C, Grant C, Grehn S et al. Evidence of poor vitamin status in coeliac patients on a gluten-free diet for 10 years. Aliment Pharmacol Ther 2002; 16: 1333-1339.
Thompson T, Dennis M, Higgins LA, Lee AR, Sharrett MK. Gluten-free diet survey: are Americans with coeliac disease consuming recommended amounts of fibre, iron, calcium and grain foods? J Hum Nutr Diet 2005; 18: 163-169.
Thompson T. Thiamin, riboflavin, and niacin contents of the gluten-free diet: is there cause for concern? J Am Diet Assoc 1999; 99: 858-862.
Lee AR, Ng DL, Dave E, Ciaccio EJ, Green PH. The effect of substituting alternative grains in the diet on the nutritional profile of the gluten-free diet. J Hum Nutr Diet 2009; 22: 359-363.
Munera-Picazo S, Ramirez-Gandolfo A, Burlo F, Carbonell-Barrachina AA. Inorganic and total arsenic contents in rice-based foods for children with celiac disease. J Food Sci 2014; 79: T122-128.
Valitutti F, De Santis B, Trovato CM et al. Assessment of mycotoxin exposure in breastfeeding mothers with celiac disease. Nutrients 2018; 10: pii: E: 336.
Scaramuzza AE, Mantegazza C, Bosetti A, Zuccotti GV. Type 1 diabetes and celiac disease: the effects of gluten free diet on metabolic control. World J Diabetes 2013; 4: 130-134.
Capriati T, Francavilla R, Ferretti F, Castellaneta S, Ancinelli M, Diamanti A. The overweight: a rare presentation of celiac disease. Eur J Clin Nutr 2016; 70: 282-284.
Dickey W, Kearney N. Overweight in celiac disease: prevalence, clinical characteristics, and effect of a gluten-free diet. Am J Gastroenterol 2006; 101: 2356-2359.
Tucker E, Rostami K, Prabhakaran S, Al Dulaimi D. Patients with coeliac disease are increasingly overweight or obese on presentation. J Gastrointestin Liver Dis 2012; 21: 11-15.
Mohsen Dehghani S, Ostovar S, Ataollahi M, Javaherizadeh H. The effect of gluten-free diet among celiac patients aged 3-12 years old on BMI during 2006 to 2014 at Nemazee Teaching hospital. Rev Gastroenterol Peru 2017; 37: 323-328.
Tortora R, Capone P, De Stefano G et al. Metabolic syndrome in patients with coeliac disease on a gluten-free diet. Aliment Pharmacol Ther 2015; 41: 352-359.
Shepherd SJ, Gibson PR. Nutritional inadequacies of the gluten-free diet in both recently-diagnosed and long-term patients with coeliac disease. J Hum Nutr Diet 2013; 26: 349-358.
Theethira TG, Dennis M, Leffler DA. Nutritional consequences of celiac disease and the gluten-free diet. Expert Rev Gastroenterol Hepatol 2014; 8: 123-129.
J. Z. Bullous diseases. St. Louis, Mosby - Year Book, 1993; 157-212.
Taylor TB, Zone JJ. Sensitivity of Transglutaminase 3 in the IgA aggregates in dermatitis herpetiformis skin to potassium iodide. J Invest Dermatol 2018; 138: 2066-2068.
Booth SA, Moody CE, Dahl MV, Herron MJ, Nelson RD. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol 1992; 98: 135-140.
Collin P, Reunala T. Recognition and management of the cutaneous manifestations of celiac disease: a guide for dermatologists. Am J Clin Dermatol 2003; 4: 13-20.
Andersson H, Mobacken H. Dietary treatment of dermatitis herpetiformis. Eur J Clin Nutr 1992; 46: 309-315.
Garioch JJ, Lewis HM, Sargent SA, Leonard JN, Fry L. 25 years' experience of a gluten-free diet in the treatment of dermatitis herpetiformis. Br J Dermatol 1994; 131: 541-545.
Coleman MD. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol 1993; 129: 507-513.
Borysiewicz CLJ. Dapsone. In: Wakelin SH, Maibach HI, Archer CB, eds. Handbook of Systemic Drug Treatment in Dermatology. Boca Raton, FL: CRC Press Taylor and Francis Group, 2015; 147-153.
Cardones AR, Hall RP 3rd. Management of dermatitis herpetiformis. Immunol Allergy Clin North Am 2012; 32: 275-281, vi-vii.
Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2001; 45: 420-434.
Junkins-Hopkins JM. Dermatitis herpetiformis: pearls and pitfalls in diagnosis and management. J Am Acad Dermatol 2010; 63: 526-528.
Glied M, Rico MJ. Treatment of autoimmune blistering diseases. Dermatol Clin 1999; 17: 431-440, x.
Sener O, Doganci L, Safali M, Besirbellioglu B, Bulucu F, Pahsa A. Severe dapsone hypersensitivity syndrome. J Investig Allergol Clin Immunol 2006; 16: 268-270.
McFadden JP, Leonard JN, Powles AV, Rutman AJ, Fry L. Sulphamethoxypyridazine for dermatitis herpetiformis, linear IgA disease and cicatricial pemphigoid. Br J Dermatol 1989; 121: 759-762.
Cooper MM. Sulfapyridine in dermatitis herpetiformis; report of case under 11 years of continuous treatment. U S Armed Forces Med J 1958; 9: 907-910.
Costello MJ. Sulfapyridine in the treatment of dermatitis herpetiformis. Arch Derm Syphilol 1947; 56: 614-628.
Goldstein BG, Smith JG, Jr. Sulfasalazine in dermatitis herpetiformis. J Am Acad Dermatol 1990; 22: 697.
Lowney ED. Use of sulfasalazine in dermatitis herpetiformis in young people. Arch Dermatol 1978; 114: 1553.
Paniker U, Levine N. Dapsone and sulfapyridine. Dermatol Clin 2001; 19: 79-86, viii.
Shah SA, Ormerod AD. Dermatitis herpetiformis effectively treated with heparin, tetracycline and nicotinamide. Clin Exp Dermatol 2000; 25: 204-205.
Silvers DN, Juhlin EA, Berczeller PH, McSorley J. Treatment of dermatitis herpetiformis with colchicine. Arch Dermatol 1980; 116: 1373-1384.
Stenveld HJ, Starink TM, van Joost T, Stoof TJ. Efficacy of cyclosporine in two patients with dermatitis herpetiformis resistant to conventional therapy. J Am Acad Dermatol 1993; 28: 1014-1015.
Wang Y, Yang B, Zhou G, Zhang F. Two cases of dermatitis herpetiformis successfully treated with tetracycline and niacinamide. Acta Dermatovenerol Croat 2018; 26: 273-275.
Willsteed E, Lee M, Wong LC, Cooper A. Sulfasalazine and dermatitis herpetiformis. Australas J Dermatol 2005; 46: 101-103.
Zemtsov A, Neldner KH. Successful treatment of dermatitis herpetiformis with tetracycline and nicotinamide in a patient unable to tolerate dapsone. J Am Acad Dermatol 1993; 28: 505-506.